Compartilhar
Informação da revista
Vol. 43. Núm. S1.
Páginas S97 (Outubro 2021)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Vol. 43. Núm. S1.
Páginas S97 (Outubro 2021)
Open Access
OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS TREATED IN A BRAZILIAN PUBLIC CANCER CENTER – A REAL WORLD EXPERIENCE OF 809 PATIENTS IN A 11 YEAR PERIOD
Visitas
1167
M Bellesso, J Pereira, L Bassolli, ANR Abdo, WFS Junior, RD Velasques, AAGS Brandão, LAPC Lage, FVR Maciel, V Rocha, H Visnadi
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil
Este item recebeu

Under a Creative Commons license
Informação do artigo
Suplemento especial
Este artigo faz parte de:
Vol. 43. Núm S1
Mais dados
Introduction

Diffuse Large B Cell Lymphoma (DLBCL) is a heterogenous disease. Factors based on clinical and simple laboratory parameters are known and widely used such as the Revised International Prognostic Index (R-IPI) and National Comprehensive Cancer Network -IPI (NCCN-IPI). Thus, we aimed to report real world experience of outcomes of DLBCL lymphoma patients treated in a Brazilian public cancer institution and evaluate the prognostic role of R-IPI and NCCN-IPI.

Methods

This is an unicenter registry study including DLBCL patients in a public tertiary cancer center in the São Paulo city, Brazil. All consecutive patients diagnosed between January 2009 and December 2020. Aged ≥ 18 years, treated with R-CHOP or R-CHOP like regimens were included. Patients with AIDS related lymphoma, or primary mediastinal lymphoma were excluded. Patients were stratified by R-IPI and NCCN-IPI and statistical analyses were performed. Progression free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier curve. All variables studied showed less than 10% of missing data and valid percents were reported.

Results

We analyzed 809 patients who met the eligibility criteria. 416 (51.5%) were males. Median age was 59.9 (44.9 – 68.2) years, 271 (31.3%) presented ECOG ≥2, 561(74.9%) advanced disease, 695 (87.4%) elevated LDH and 638 (82.2%) extra-nodal infiltration. All cases were possible to be classified by prognostic score 465(57.5%) were classified as high risk or high-intermediate NCCN-IPI (≥ 4 pts) and 411 (50.8%) poor prognosis by R-IPI (≥ 3 pts). It was possible evaluated response status after first line treatment in 678 patients,456 (67.2%) achieved Complete Response. Four years OS and PFS for the entire patient cohort were 65.3% 95CI (61.5-68.9) and 60.4% 95CI (56.5-64.), respectively. Median follow-up 4.6 95CI (4.2-5.0) years. Patients classified as very good (0), good (1-2) and poor (≥ 3) prognosis by R-IPI presented 4-years OS 94%, 75.2% and 52.8%, p < 0.0001. About 4-years PFS: 94%, 68.8%, 48.2%, p < 0.001, respectively. According to NCCN-IPI and risk group: low (0-1), low-intermediate (2-3), high-intermediate (4-5) and high risk 4 years OS: 95.5%, 75.4%, 60.3%, 35.9%, p < 0.0001) and 4-years PFS: 93.7%, 69.7%, 54.7% and 33.3%, p < 0.001, respectively.

Conclusion

In this large cohort of DLBCL patients diagnosed and treated in a public University center in Brazil, we have observed a higher frequency of patients with unfavorable prognosis 57.5% NCCN IPI (≥4 pts) and 50.8% R IPI (≥3 pts) when compared to data published in the literature 39% and 45%, respectively. OS and PFS are comparable to data of literature according to NCCN IPI and R IPI scores. Both scores discriminate groups of patients with DLBCL in a middleincome country and may be used to study further strategies to improve outcomes of patients with poor prognosis.

O texto completo está disponível em PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas